Hence, while the expression of PD-1 on tumor ILC-1s has been extensively reported, several questions remain; namely, whether tumor alarmins drive PD-1 expression and whether PD-1 intrinsically inhibits antitumor function of ILCs within the TME in the absence of exogenous IL-33. The gene discussed is IL33; the disease is neoplasm.